 <h1>Natalizumab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to natalizumab: intravenous solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Solution)</p><p>Progressive Multifocal LeukoencephalopathyNatalizumab increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability.Risk factors for PML include the presence of anti-JC virus antibodies, duration of therapy, and prior use of immunosuppressants. These factors should be considered in the context of expected benefit when initiating and continuing treatment with natalizumab.Monitor patients, and withhold natalizumab immediately at the first sign or symptoms suggestive of PML.Because of the risk of PML, natalizumab is available only through a restricted distribution program called the TOUCH® Prescribing Program.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, natalizumab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking natalizumab:</p><p>
<i>More common</i>
</p><ul>
<li>Bladder pain</li>
<li>blistering, crusting, irritation, itching, or reddening of the skin</li>
<li>bloody or cloudy urine</li>
<li>body produces substance that can bind to drug making it less effective or cause side effects</li>
<li>cough</li>
<li>difficult, burning, or painful urination</li>
<li>difficulty with swallowing</li>
<li>dizziness</li>
<li>fast heartbeat</li>
<li>frequent, strong, or increased urge to urinate</li>
<li>hives, itching, skin rash</li>
<li>itching of the vagina or genital area</li>
<li>lower back or side pain</li>
<li>pain during sexual intercourse</li>
<li>passing urine more often</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>thick, white vaginal discharge with no odor or with a mild odor</li>
<li>tightness in the chest</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Blurred vision</li>
<li>changes in behavior</li>
<li>chest pain</li>
<li>confusion</li>
<li>difficult or labored breathing</li>
<li>fainting or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>feeling of warmth</li>
<li>feeling unusually cold</li>
<li>fever</li>
<li>gaseous abdominal or stomach pain</li>
<li>nausea</li>
<li>redness of the face, neck, arms, and occasionally, upper chest</li>
<li>shivering</li>
<li>sneezing</li>
<li>sore throat</li>
<li>stomach fullness</li>
<li>sweating</li>
<li>thoughts of killing oneself</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Back, leg, or stomach pains</li>
<li>black, tarry stools</li>
<li>bleeding gums</li>
<li>chills</li>
<li>dark urine</li>
<li>drowsiness</li>
<li>general body swelling</li>
<li>headache</li>
<li>heavier menstrual periods</li>
<li>loss of appetite</li>
<li>nosebleeds</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>seizures</li>
<li>unusual bleeding or bruising</li>
<li>vomiting</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of natalizumab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Cracked, dry, scaly skin</li>
<li>diarrhea</li>
<li>difficulty with moving</li>
<li>discouragement</li>
<li>feeling sad or empty</li>
<li>irregular menstruation</li>
<li>irritability</li>
<li>loss of interest or pleasure</li>
<li>muscle pain or stiffness</li>
<li>pain, cramps, or heavy bleeding</li>
<li>pain in the joints</li>
<li>stomach soreness or discomfort</li>
<li>swollen glands</li>
<li>trouble concentrating</li>
<li>trouble sleeping</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Absent, missed, or irregular menstrual periods</li>
<li>chest discomfort</li>
<li>local bleeding</li>
<li>shakiness in the legs, arms, hands, or feet</li>
<li>stopping of menstrual bleeding</li>
<li>trembling or shaking of the hands or feet</li>
</ul><p>
<!-- end intravenous solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to natalizumab: intravenous concentrate</i></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Acute retinal necrosis (ARN), blindness, decreased visual acuity, redness, eye pain<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (38%)</p>
<p><b>Common</b> (1% to 10%): Vertigo, somnolence, tremor, dizziness</p>
<p><b>Uncommon</b> (0.1% to 1%): Progressive multifocal leukoencephalopathy (PML)</p>
<p><b>Frequency not reported</b>: Tremor<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (22%), lower respiratory tract infection (17%)</p>
<p><b>Common</b> (1% to 10%): Pharyngolaryngeal pain, cough, sinusitis, nasopharyngitis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Depression (19%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (17%), gastroenteritis (11%), abdominal discomfort (11%), diarrhea (10%)</p>
<p><b>Common</b> (1% to 10%): Dyspepsia, constipation, flatulence, aphthous stomatitis, tooth infection, tonsillitis</p>
<p><b>Frequency not reported</b>: Vomiting<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Influenza-like illness (12%)</p>
<p><b>Common</b> (1% to 10%): Herpes, tonsillitis, viral infection, immunogenicity<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Abnormal liver function test</p>
<p><b>Postmarketing reports</b>: Serious liver injuries, increased liver enzymes, hyperbilirubinemia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (27%)</p>
<p><b>Common</b> (1% to 10%): Tooth infections, toothache, rigors</p>
<p><b>Frequency not reported</b>: Flushing, feeling cold, pyrexia<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Localized hypersensitivity reactions<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (21%), vaginitis (10%)</p>
<p><b>Common</b> (1% to 10%): Irregular menstruation, dysmenorrhea, amenorrhea, ovarian cyst, urinary incontinence, urinary urgency/frequency<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (19%), pain in extremity (16%), back pain (12%)</p>
<p><b>Common</b> (1% to 10%): Rigors, muscle cramp, joint swelling<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (12%)</p>
<p><b>Common</b> (1% to 10%): Dermatitis, pruritus, night sweats, dry skin, urticaria<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Immediate or delayed hypersensitivity reactions, seasonal allergy</p>
<p><b>Frequency not reported</b>: anaphylaxis/anaphylactoid reaction<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (less than 0.1%): Anemia, hemolytic anemia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Weight increased, weight decreased, peripheral edema<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest discomfort<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_2">2. "Product Information. Tysabri (natalizumab)." Elan Pharmaceutical/Athena Neurosciences Inc, South San Francisco, CA. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about natalizumab</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>96 Reviews</li>
<li>Drug class: selective immunosuppressants</li>
<li>FDA Alerts (1)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Natalizumab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Tysabri</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Crohn's Disease, Maintenance</li>
<li>Multiple Sclerosis</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to natalizumab: intravenous concentrate</i></p><h3>Ocular</h3><p><b>Frequency not reported</b>: Acute retinal necrosis (ARN), blindness, decreased visual acuity, redness, eye pain<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (38%)</p><p><b>Common</b> (1% to 10%): Vertigo, somnolence, tremor, dizziness</p><p><b>Uncommon</b> (0.1% to 1%): Progressive multifocal leukoencephalopathy (PML)</p><p><b>Frequency not reported</b>: Tremor<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory tract infection (22%), lower respiratory tract infection (17%)</p><p><b>Common</b> (1% to 10%): Pharyngolaryngeal pain, cough, sinusitis, nasopharyngitis<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Depression (19%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (17%), gastroenteritis (11%), abdominal discomfort (11%), diarrhea (10%)</p><p><b>Common</b> (1% to 10%): Dyspepsia, constipation, flatulence, aphthous stomatitis, tooth infection, tonsillitis</p><p><b>Frequency not reported</b>: Vomiting<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Influenza-like illness (12%)</p><p><b>Common</b> (1% to 10%): Herpes, tonsillitis, viral infection, immunogenicity<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Abnormal liver function test</p><p><b>Postmarketing reports</b>: Serious liver injuries, increased liver enzymes, hyperbilirubinemia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (27%)</p><p><b>Common</b> (1% to 10%): Tooth infections, toothache, rigors</p><p><b>Frequency not reported</b>: Flushing, feeling cold, pyrexia<sup>[Ref]</sup></p><h3>Local</h3><p><b>Frequency not reported</b>: Localized hypersensitivity reactions<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Very common</b> (10% or more): Urinary tract infection (21%), vaginitis (10%)</p><p><b>Common</b> (1% to 10%): Irregular menstruation, dysmenorrhea, amenorrhea, ovarian cyst, urinary incontinence, urinary urgency/frequency<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (19%), pain in extremity (16%), back pain (12%)</p><p><b>Common</b> (1% to 10%): Rigors, muscle cramp, joint swelling<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (12%)</p><p><b>Common</b> (1% to 10%): Dermatitis, pruritus, night sweats, dry skin, urticaria<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Immediate or delayed hypersensitivity reactions, seasonal allergy</p><p><b>Frequency not reported</b>: anaphylaxis/anaphylactoid reaction<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Rare</b> (less than 0.1%): Anemia, hemolytic anemia<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Common</b> (1% to 10%): Weight increased, weight decreased, peripheral edema<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Chest discomfort<sup>[Ref]</sup></p><p id="ref_1">1. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_2">2. "Product Information. Tysabri (natalizumab)." Elan Pharmaceutical/Athena Neurosciences Inc, South San Francisco, CA. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2>More about natalizumab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>96 Reviews</li>
<li>Drug class: selective immunosuppressants</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Natalizumab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Crohn's Disease, Maintenance</li>
<li>Multiple Sclerosis</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>